TNF and cancer: In the post-marketing ORAL surveillance study of patients with rheumatoid arthritis with at least one cardiovascular risk factor, tofacitinib has been associated with increased risk of all-cause mortality, including sudden death, thromboembolic disease, and malignancies when compared to patients treated with anti-TNF [106].